Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 187(1): 113-123, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-27667787

RESUMO

Tolerogenic dendritic cells (tolDC) are a new immunotherapeutic tool for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders. We have established a method to generate stable tolDC by pharmacological modulation of human monocyte-derived DC. These tolDC exert potent pro-tolerogenic actions on CD4+ T cells. Lack of interleukin (IL)-12p70 production is a key immunoregulatory attribute of tolDC but does not explain their action fully. Here we show that tolDC express transforming growth factor (TGF)-ß1 at both mRNA and protein levels, and that expression of this immunoregulatory cytokine is significantly higher in tolDC than in mature monocyte-derived DC. By inhibiting TGF-ß1 signalling we demonstrate that tolDC regulate CD4+ T cell responses in a manner that is at least partly dependent upon this cytokine. Crucially, we also show that while there is no significant difference in expression of TGF-ßRII on CD4+ T cells from RA patients and healthy controls, RA patient CD4+ T cells are measurably less responsive to TGF-ß1 than healthy control CD4+ T cells [reduced TGF-ß-induced mothers against decapentaplegic homologue (Smad)2/3 phosphorylation, forkhead box protein 3 (FoxP3) expression and suppression of (IFN)-γ secretion]. However, CD4+ T cells from RA patients can, nonetheless, be regulated efficiently by tolDC in a TGF-ß1-dependent manner. This work is important for the design and development of future studies investigating the potential use of tolDC as a novel immunotherapy for the treatment of RA.


Assuntos
Artrite Reumatoide/terapia , Linfócitos T CD4-Positivos/imunologia , Células Dendríticas/imunologia , Tolerância Imunológica , Imunoterapia/métodos , Fator de Crescimento Transformador beta1/metabolismo , Artrite Reumatoide/imunologia , Células Cultivadas , Colecalciferol/farmacologia , Células Dendríticas/efeitos dos fármacos , Células Dendríticas/transplante , Dexametasona/farmacologia , Fatores de Transcrição Forkhead/metabolismo , Humanos , Imunomodulação , Interleucina-12/genética , Interleucina-12/metabolismo , Ativação Linfocitária , Proteína Smad2/metabolismo
2.
Br J Dermatol ; 176(6): 1617-1623, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27943248

RESUMO

BACKGROUND: Little is known about U.K. dermatologists' treatment approaches towards adult patients with recalcitrant moderate-to-severe atopic eczema. OBJECTIVES: We wanted to learn about (i) treatment approaches used for this disease in the U.K.; (ii) factors that influence treatment decisions and (iii) perceived gaps in evidence on treatment safety and efficacy, and priorities for future trials. METHODS: We conducted an online survey of consultant-level dermatologists in the U.K. RESULTS: Sixty-one respondents from over 30 centres reported on management of moderate-to-severe atopic eczema in adults, outwith the context of an acute flare. Phototherapy or psoralen-ultraviolet A was the most common therapeutic modality chosen first line (46%), and this was usually narrowband ultraviolet B. Systemic therapy was chosen as a first-line approach by 36% of dermatologists. Azathioprine was the commonest drug reported being used as first line followed by oral corticosteroids, ciclosporin and methotrexate. Methotrexate was the most common second-line treatment of respondents. The key factors that influenced decision making on the use of phototherapy and systemic agents were the respondent's clinical experience, results of baseline tests (systemic agents) and knowledge of both efficacy and acute and chronic side-effect profiles. The most important evidence gaps identified were the relative effectiveness of treatments, the alternatives to current approaches and the safety of long-term maintenance treatment. With regard to future trials, respondents suggested that priority should be given to studies involving methotrexate. CONCLUSIONS: While survey study designs have limitations, we found that phototherapy, in particular narrowband ultraviolet B, was respondents' preferred first-line treatment for adults with recalcitrant moderate-to-severe atopic eczema, perhaps reflecting access to, and clinical experience of, this approach. Azathioprine is widely used as a longer-term maintenance treatment.


Assuntos
Dermatite Atópica/terapia , Dermatologistas , Padrões de Prática Médica , Adulto , Tomada de Decisão Clínica , Consultores , Fármacos Dermatológicos/uso terapêutico , Previsões , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Avaliação das Necessidades , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/uso terapêutico , Terapia Ultravioleta/métodos , Reino Unido
3.
J Soc Psychol ; 139(3): 323-34, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10410619

RESUMO

This study examined the use of sexual orientation as a meaningful social category and the consequences of using this category. The sample consisted of 260 U.S. college students who viewed a video and completed a 29-item scale (L. L. Thompson & J. Crocker, 1990) and the 7-item Homophobia Scale (R. A. Bouton et al., 1987). Results showed that participants' adjective ratings of targets favored gay men. Participants did not exhibit greater bias toward gay men when provided with justification. However, there was a pattern of bias in which participants showed favoritism toward heterosexual male targets when provided with no justification for bias.


Assuntos
Homossexualidade Masculina/psicologia , Preconceito , Estudantes/psicologia , Adulto , Feminino , Humanos , Masculino , Universidades
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...